NCT03355196View on ClinicalTrials.gov

First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

March 26, 2019

Study Completion Date

March 26, 2019

Conditions
Patients With Moderate Knee Osteoarthritis (30 - 65 Years)
Interventions
DRUG

LRX712

Ascending single dose on Day 1

DRUG

Placebo

Ascending single dose on Day 1

Trial Locations (1)

2333 CL

Novartis Investigative Site, Leiden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT03355196 - First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients | Biotech Hunter | Biotech Hunter